Diatide gets payment for AcuTect

Article

Only days after the Food and Drug Administration cleared Diatide's acute venous thrombosis imaging agent AcuTect (SCAN 9/30/98), the Londonderry, NH, radiopharmaceutical firm received a $2 million milestone payment from marketing partner Nycomed Amersham

Only days after the Food and Drug Administration cleared Diatide's acute venous thrombosis imaging agent AcuTect (SCAN 9/30/98), the Londonderry, NH, radiopharmaceutical firm received a $2 million milestone payment from marketing partner Nycomed Amersham of Buckinghamshire, U.K. The cash is the second payment Diatide has received from Nycomed Amersham in the last two months: In August, Diatide received $2 million for filing a new drug application for NeoTect, its lung cancer imaging agent.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.